EU grants orphan status to OXiGENE's ovarian cancer drug

OXiGENE's experimental ovarian cancer drug Zybrestat obtained orphan-drug designation from the European Medicines Agency. The drug, in combination with Roche Holding's Avastin, is in a midstage study for patients with advanced ovarian cancer. Data from the trial could be released next year.

View Full Article in:

Wall Street Journal (tiered subscription model), The · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC